Smokers having Activating EGFR Mutant Non-Small CellLung Cancer Might Benefit from EGFR-TKI Treatment –Single-Center Experience


ERCELEP Ö., AKIN TELLİ T., ALAN Ö., Hasanov R., Şimşek E. T., Babacan N., ...Daha Fazla

TURK ONKOLOGI DERGISI-TURKISH JOURNAL OF ONCOLOGY, cilt.35, sa.3, ss.334-339, 2020 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 35 Sayı: 3
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5505/tjo.2020.2207
  • Dergi Adı: TURK ONKOLOGI DERGISI-TURKISH JOURNAL OF ONCOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.334-339
  • Anahtar Kelimeler: Epidermal growth factor receptor, smoking, tyrosine kinase inhibitors, GROWTH-FACTOR-RECEPTOR, OPEN-LABEL, NEVER SMOKERS, 1ST-LINE TREATMENT, CIGARETTE-SMOKING, GENE-MUTATIONS, PHASE-III, GEFITINIB, CHEMOTHERAPY, RESISTANCE
  • Marmara Üniversitesi Adresli: Evet

Özet

OBJECTIVE